Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

Clinical trial NCT00345345 · COMPLETED

Trial details

NCT number: NCT00345345
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

T-LGL Lymphoproliferative Disorders

Start date: 2006-10-17
Primary completion: 2017-08-01
Enrollment: 29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.